Curcumin and blood lipid levels: an updated systematic review and meta-analysis of randomised clinical trials

Arch Physiol Biochem. 2022 Dec;128(6):1493-1502. doi: 10.1080/13813455.2020.1779309. Epub 2020 Jul 6.

Abstract

The present study was designed to indicate the protective effects of curcumin on dyslipidemia. Main databases were searched to recognise randomised clinical trials evaluating the effect of curcumin on blood lipid profiles. The pooled odds ratio with a 95% confidence interval (CI) was used to evaluate the effect of curcumin on blood lipid parameters. HDL-C levels in the curcumin group were 0.04-fold lower than placebo (95% CI:-0.36-0.29; Z = 0.23; p = .82). LDL-C levels in the curcumin group reduced by 0.17 versus the placebo group (95% CI: -0.43-0.09; Z = 1.27; p = .2). TC levels in the curcumin group were 0.21 lower versus the placebo group (95% CI: -0.55-0.13; Z = 1.22; p = .22). TG level in the curcumin group were 0.05 lower versus the placebo (95% CI: -0.20-0.11; Z = 0.58; p = .56). This study suggests that curcumin may reduce blood lipid levels and can be used as a hypolipidemic agent.

Keywords: Curcumin; blood lipid profile; curcuminoid; turmeric.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Cholesterol, LDL
  • Curcumin* / pharmacology
  • Curcumin* / therapeutic use
  • Dyslipidemias* / drug therapy
  • Humans
  • Hypolipidemic Agents / therapeutic use
  • Lipids
  • Randomized Controlled Trials as Topic
  • Triglycerides

Substances

  • Curcumin
  • Cholesterol, LDL
  • Lipids
  • Hypolipidemic Agents
  • Triglycerides